tion of a substance, the choice of a suitable dissolution medium
INTRODUCTION some cases we also tested the dissolution behavior in fed state simulating intestinal fluid (FeSSIF), to gain a better understandDissolution tests are a standard method used to ensure the ing of the interaction between pH and bile effects on the dissolubatch to batch conformity of oral dosage forms. In research tion of the drug substance. and development, dissolution tests are often used to assist in the formulation development of IR and MR dosage forms. Today most pharmacopeias describe four different dissolution test apparatuses: basket, paddle, reciprocating cylinder and MATERIALS AND METHODS flow-through cell. The most often recommended methods are the basket and the paddle because of their precise and simple set-up and handling (1). Even though these closed systems Materials normally simulate only one GI environment within a given run, they are suitable for characterizing the drug release from Sodium taurocholate 98 % pure, Lot # 15H5001 was purmany formulations.
chased from Sigma-Aldrich Chemie GmbH (Deisenhofen, Germany). Egg-phosphatidylcholine, Lipoid E PC 99.1% pure, lot # Egg-phosphatidylcholine, Lipoid E PC 99.1% pure lot #12091-1, was a gift from Lipoid GmbH (Ludwigshafen, 1 Institut für Pharmazeutische Technologie, Johann Wolfgang Goethe-Germany).
Dissolution
LiChoCART 125-4 LiChospher 60 Rp-select B (5 m, Merck, Darmstadt, Germany) with a guard column was used. The An Erweka Type DT 6 dissolution tester (Erweka, Heusen-mobile phase was a mixture of acetonitrile and sodium dihydrostamm/Germany) was used for all dissolution studies. The appa-gen phosphate buffer (25 mM, pH 4.5) in a ratio of 45:55. The ratus was calibrated according to the USP 23. The dissolution in flow rate was 1 ml/min and the wavelength was 230 nm. The various test media was tested using the paddle method (method 2 retention time of glibenclamide (8 minutes) separated the drug USP 23), employing 500 or 900 ml of dissolution medium at adequately from other media components. No drug instability a temperature of 37 Ϯ 0.5ЊC, and an agitation rate of 75 rpm. was detected in any media within the assay time. A six point standard curve was constructed for each dissolution media and Composition of Dissolution Media linearity was confirmed throughout a detection range of 0.1% to 150% of the expected drug content. The data were stored in Simulated Intestinal Fluid: SIF sp , which has a pH of 7.5, an a Shimadzu C-R5A integrator (Shimadzu, Kyoto, Japan) was composed as SIF, USP 23, without pancreatin (2) .
and were transferred to Excel (Microsoft, CO) for data analysis. Fasted State Simulating Intestinal Fluid: FaSSIF contains 3 mM sodium taurocholate and 0.75 mM lecithin and has a pH Surface Tension, pH Measurements, and Particle Size of 6.5 and an ionic strength of 0.15 (13). FaSSIF slt (sine lecithin, taurocholate) was composed as FaSSIF, but without lecithin Surface tension of the various dissolution media was meaand sodium taurocholate.
sured at 20ЊC by the ring method using a tensiometer (Lauda Fed State Simulating Intestinal Fluid: FeSSIF contains 15 TE 1, Lauda, Germany). The change in pH was measured 30 mM sodium taurocholate and 3.75 mM lecithin and has a pH minutes after adding a tablet to 10 ml of water. The particle of 5.0 and an ionic strength of 0.3 (13). FeSSIF slt (sine lecithin, size was determined using a light microscope (Carl Zeiss, Jena) taurocholate) was composed as FeSSIF, but without lecithin equipped with a scale. The quality control laboratory at Hoechst and sodium taurocholate.
AG determined the surface area of both powders (14). Simulated Gastric Fluid: SGF was prepared according to the USP 23, without pepsin (2) .
Dissolution Test Conditions and IVIVC-Requirements Buffer pH 6.0: was a 20 mM potassium phosphate buffer for Glibenclamide Products of pH 6.0.
Studies carried out by the central quality control laboratory Protocol for Glibenclamide 3.5 mg Tablets and of the German pharmacists (ZL) used 900 ml of a buffer with Glibenclamide Powder a pH of 7.4, and USP apparatus 2 with an agitation rate of 75 rpm. A relationship was found between the extent of dissolution Dissolution tests were performed on Euglucon Nா 3.5 in the first 10 minutes and the glucose levels in the first 3 hours mg Tablets hereafter designated as ,,reference product,, (Lot # (15). According to these findings, a new product should release 01N620, Boehringer Mannheim/Hoechst, Germany), on Glunot less than 80% of the drug within 10 minutes in vitro in kovitalா 3.5 mg Tablet, hereafter designated as ,,test product,, order to achieve bioequivalence to the pioneer product (15). (Lot #09601, Dr. August Wolff Arzneimittel, Bielefeld, Germany), on glibenclamide powder (Lot # N392, Hoechst AG, Frankfurt, Germany), and on glibenclamide microfine powder In Vitro/In Vivo Correlation (Lot #N326, Hoechst AG, Frankfurt, Germany).
The percent absorbed for both formulations was calculated from the bioequivalence study undertaken at the ZL (15) using Sampling Procedure the software Kinetica (InnaPhase, 77420 Champs sur Marne, France). The data were calculated using the Loo-Riegelman Samples were removed using a 5 ml Fortuna Optima two compartment model. Because no i.v. data were available, syringe fitted with custom made steel tubing equipped with a the oral data after C max were used to calculate pharmacokinetic filter to facilitate representative sampling. 15 seconds before parameters. The in vivo data for the time points at 30, 60, 90, the sample was taken, the steel tube was lowered into the and 120 min. were then correlated with the in vitro dissolution dissolution medium. The drawn sample volume was replaced data at 5, 10, 15, and 30 min. with the same volume of blank dissolution medium from a separate vessel, also held at a temperature of 37 Ϯ 0.5ЊC. The sample was then filtered through a 0.45 m (Schleicher & Computer Simulation Schuell FP 030/20) cellulose acetate filter, discarding the first A useful tool to predict the plasma concentrations of a drug 2-3 ml. Samples were kept in 25 ϫ 10 mm screw cap glass is the Biopharmaceutics Classification System (BCS) (16,17). Key test tubes until analysis. Filter and steel tubing were checked parameters are permeability and the concentration at the intestinal for adsorption, but no significant loss of drug was observed.
membrane, which is generated by drug dissolution and is therefore dependent on drug solubility. The calculations in Gastro Plus HPLC Analysis are based on these principles and the model is known as the advanced compartmental absorption and transit model (ACAT) A Merck Hitachi HPLC-system composed of an L 7200 Auto sampler, a pump L7100 and an UV Detector L4250 (Merck (18). A closer description of the software can be found on the company's home page: http://www.simulations-plus.com. Hitachi, Darmstadt, Germany) was used for sample analysis. 30 l of the dissolution samples were directly injected on the The computer simulation was performed using Gastro Plus Version 1.05 (Simulations Plus, Lancaster, CA). The column without further preparation. As an analytical column input data for the chemical properties were taken from literature the unfavorable pH, only 2-4% dissolved within one hour. At pH 6.5, dissolution was still poor in absence of bile components, (11,19) or were calculated using suitable software. The log P was calculated by free software available on the Internet (http:// but in FaSSIF 17% of micronized powder and 3-6% of normal powder dissolved within an hour. At pH 7.5 (SIF sp ) differences esc.syrres.com), the diffusion coefficient was calculated according to the Hayduk-Laudi-Correlation (20) and the P eff in dissolution with particle size were also observed. The more favorable pH failed to compensate for the lack of bile compowas estimated by the simulation software. The particle radius was set at 50 , corresponding to the microscopic analysis of nents, though, with the result that less than 10% of either powder dissolved with in one hour. the powder. The "solubility" for each formulation was based on the maximum amounts dissolved in FaSSIF in the dissoluDissolution of the Two Glibenclamide Formulations: tion tests.
Effect of Volume The pharmacokinetic parameters, clearance, volume of distribution, K 12 , K 21 used in Gastro Plus for the simulation In a preliminary series of experiments using the two formuwere calculated using Kinetica. Model fits to the experimental lations, the influence of the media volume on the dissolution in vivo data confirmed that the pharmacokinetics could be best rate was tested. Both formulations were tested in 500 and 900 described by a two-compartment model (21), which was then ml of SIF sp by the paddle method. The volume appeared to used for the simulation in Gastro Plus. have no effect on the release rate of the test formulation, while the release from the reference formulation was decreased at the Data Analysis and Statistics lower volume, see Table 2 .
Dissolution data is presented as mean Ϯ sd (n ϭ 3). Dissolution of the Reference Formulation in 500 ml of Linear regression was used to test for correlation between the Different Media dissolution behavior in different media and the in vivo data In pH 7.5 buffer (SIF sp ) over 90% of the drug content (SigmaPlot 5.0, SPSS, Chicago). The goodness of fit of the of the reference product dissolved within 10 minutes. This simulated to the observed curve was assessed graphically by formulation therefore met the ZL criterion of 80% release within plotting the observed data versus the simulated data using Sig-10 minutes. After 30 minutes approximately 100% of the drug maPlot software (SigmaPlot 5.0, SPSS, Chicago). Linear regrescontent was dissolved (Fig. 1) . In pH 6.5 buffer (FaSSIF slt ) sion was applied to the data to determine whether they fell only 34% of the drug content dissolved in one hour. This within the predetermined confidence interval of 99%.
concentration appears to correspond to saturation with glibenclamide in 500 ml at this pH and for this formulation. In a pH RESULTS 6.0 buffer only half this amount (18%) was dissolved after one hour. In pH 5.0 buffer (FeSSIF slt ) only 1.4% of the drug could Dissolution Results with Glibenclamide Powder be dissolved in 500 ml. In dissolution media containing lecithin and sodium taurocholate the dissolution rate was improved. In The microscopic analysis of the two powders showed a FaSSIF (pH 6.5) up to 87 % of the drug content was dissolved, significant difference in the particle size and size distribution.
while in FeSSIF (pH 5.0) 18% of the glibenclamide was disWhile 99% of the microfine powder had a particle size of solved, see Fig. 1 . approximately 50 m, the "normal" powder showed particle sizes between 50 m and 350 m. According to the manufacDissolution of the Test Formulation in 500 ml of turer, the surface area of the microfine powder is 4.6 times Different Media higher than the normal powder (14). In pH 5 buffer (FeSSIF slt ) no dissolution was detected within 60 minutes for either powder.
The release of glibenclamide from the test formulation in SIF sp was not as fast as for the reference product. The test Addition of bile components improved dissolution, but due to taurocholate up to 40% of the drug dissolved in one hour, which using the paddle method (method 2 USP 23), employing 500 ml of is less than the half the amount from the reference product dissolution medium at a temperature of 37 Ϯ 0.5ЊC, and an agitation dissolved in the same medium. In FaSSIF slt , however, approxi-rate of 75 rpm. mately 31% of the drug dissolved in one hour, nearly the same as determined for the reference product in the same medium. In FeSSIF slt no drug could be detected after one hour of testing, IVIVC see Fig. 2 .
The results of the in vitro/in vivo correlation are shown Surface Tension and pH Measurements in Fig. 3 . The graph shows that if FaSSIF was used as the dissolution medium both formulations showed an essentially Surface tension of the different media was determined.
linear relationship. The slopes of the regression lines using The value for water was found to be 72 dyne/cm while FaSSIF FaSSIF are similar at 3.27 for the test and 3.33 for the reference showed a much lower value of 49 dyne/cm. The reference product. In contrast, the correlation curves in SIF are not linear formulation lowered the surface tension of 500 ml SIF from and have obviously different curvatures (slopes of the best 65 to 49 dyne/cm. The test formulation changed the surface linear fits are 0.9 and 1.88 respectively). tension of 500 ml SIF from 65 to 62 dyne/cm. This indicates that the reference product contains more/more efficient surfacSoftware Analysis of the In Vivo Data and Simulations tants than the test product. These may improve wetting of glibenclamide and thus have an impact on its dissolution rate A comparison of the different pharmacokinetic parameters (4). Both formulations increased the pH of 10 ml of water from obtained by the Gastro Plus simulation, pharmacokinetic fit-6.18 to 6.76 for the reference and to 6.97 for the test formulation. ting (with Kinetica) and those reported by the manufacturer This slight increase in the pH indicates that little or no pH of the test formulation is given in Table 3 . While the data increasing excipients were used in either formulation to encour-provided by the manufacturer overestimate the actual (taken age the dissolution. from the raw data) C max values for the two formulations, both Gastro Plus and Kinetica underestimated C max . The observed mean plasma levels from the bioequivalence study Fig. 1 . Dissolution of the reference formulation (Ϯ sd) in various test media using the paddle method (method 2 USP 23), employing 500 Fig. 3 . In vitro/in vivo relationship of the two commercially available ml of dissolution medium at a temperature of 37 Ϯ 0.5ЊC, and an agitation rate of 75 rpm.
formulations in SIF sp and FaSSIF. are shown in Fig. 4 . The t max values in the three parameter sets The Dissolution Number (Dn), which is the ratio between transit time and dissolution time, can be increased by reducing the also exhibit differences (see Table 3 ). The lower AUC obtained with Gastro Plus seems to be due to the lower C max and t max particle size (17). Another way to improve oral absorption is to decrease the Dose Number, which is defined as the ratio values, see Fig. 3 . A close simulation of both observed plasma curves was only successful when the dissolution results of the of dose concentration to drug solubility (17). In the case of glibenclamide, physiological concentrations of solubilizers like experiments in FaSSIF were used in Gastro Plus for each formulation separately. The goodness of fit for the test formula-lecithin and sodium taurocholate can improve the solubility substantially (compare results for both powders in FaSSIF and tion showed that, except for the 1 and 1.5 hour data, all data pairs (simulated vs. observed) were within a 99% confidence SIF sp ). Furthermore, the interaction of the lecithin/taurocholate micelles with excipients can significantly improve the solubility interval, and the regression coefficient was 0.89. For the reference formulation all data points, except for 3 hours, were within of the drug, as shown for both oral formulations in FaSSIF.
The small change in pH of an aliquot of water due to addition a 99% confidence interval with a regression coefficient of 0.97.
of the dosage form indicates that the increase in the solubility was due to surface-active excipients in the formulations and DISCUSSION not to addition of pH increasing excipients. Two different glibenclamide powders are commercially Although, most formulations in Germany contain a dose available from Hoechst AG. The dissolution results in different of 3.5 mg glibenclamide, there are also products marketed in media show that the rate and extent of drug dissolution highly Europe containing 5 mg drug (23) . It has been shown that depends on the wetting characteristics of the medium used as dosage forms containing 3.5 mg have the same therapeutic well as on the particle size of the powder. The smaller particles effect as formulations with 5 mg (24) . This unusual result with the higher surface area (microfine powder) dissolved faster can be explained by the slower and presumably incomplete compared to the bigger particles of the non-micronized powder. absorption of the larger drug particles used in the 5 mg This could result in incomplete absorption from the coarser formulations. powder, depending on the particle size, as the transit time may
The biopharmaceutical quality of different glibenclamide be too short for complete dissolution of the drug. In the case products was investigated by Blume et al. (23) . The results where particle size is large, glibenclamide can be considered showed high variability in the dissolution behavior, even for the as a dissolution-limited drug (Dissolution Number Ͻ 1) (4,22). same brand name product manufactured in different countries.
Systematic investigations by the ZL of the rate and extent of bioavailability of glibenclamide products on the German market containing 3.5 mg drug and exhibiting different dissolution properties have shown that bioavailability can be clearly correlated with the dissolution behavior of glibenclamide formulations (15). From the bioavailability studies it is known that such differences in dissolution are also clinically relevant (23) . Investigations have shown, in particular, that the plasma concentrations during the first three hours after administration are of major importance for the pharmacodynamic effect (24) . The rate of absorption in the first three hours is, in turn, strongly correlated with the rate of dissolution during the first fifteen minutes in SIF sp . The in vivo data published by ZL show the same tendency as our in vitro results for the reference product and the test formulation.
A close linear relationship between percent dissolved found in our investigation, see Fig. 3 . The improved linearity
